Human evidence for VIP is limited — pilot studies, withdrawn trials, or completed trials without posted results. Off-label / exploratory data exists for 10 additional indications (Pharmacokinetic / healthy volunteer studies; Covid19).

Research Evidence
Evidence shape
Human evidence for VIP is limited — pilot studies, withdrawn trials, or completed trials without posted results. Off-label / exploratory data exists for 10 additional indications (Pharmacokinetic / healthy volunteer studies; Covid19).
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How VIP is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
10 completed trials identified; trial dosing not reliably extracted from registry data.
Clinician protocols dose 200 µg daily subQ (2 sources).
Anecdotal reports involving VIP are positive regarding its use for inflammatory conditions (3 of 3 reports) and neuroprotection/headache relief (2 of 3 reports positive). However, specific dosing information from community posts is not available.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Regulatory safety notes
Peptide feedback
0 forum repliesLive community discussion for VIP, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.